MDACC Study No:2007-0183 ( NCT No: NCT00506597)
Title:Erwinia L-asparaginase for Injection IND 290
Principal Investigator:Robert J. Wells
Treatment Agent:Erwinia Asparaginase
Study Status:Terminated
Study Description:The goal of this clinical research study is to allow doctors to use Erwinia
L-Asparaginase (Erwinase®) as a replacement for patients who are allergic to
E.coli L-asparaginase or Pegylated E.coli L-asparaginase as part of the
treatment for acute lymphoblastic leukemia (ALL) or T or B cell lymphoma.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma; Pediatrics
Phase of Study:N/A
Treatment Agents:Erwinia Asparaginase
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Based on the ALL treatment protocol that the patient is enrolled.
Supported By:EUSA Pharma, Inc.
Return Visit:Based on the ALL treatment protocol that the patient is enrolled.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Robert J. Wells
For Clinical Trial Enrollment:713-563-1499
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults